Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition

NMD Pharma and academic collaborators

1. 01

   Weak older individuals exhibit NMJ transmission failure that correlates with severity of muscle weakness

2. 02

   Aged rodents reproduce the same NMJ transmission failure, localized to loss of muscle fiber excitability at the junction

3. 03

   The defect is distinct from cholinergic synaptic transmission abnormalities - a novel sarcopenia mechanism

4. 04

   Immunohistochemistry across species identified localized reduction of NaV1.4 at the post-synaptic NMJ membrane

5. 05

   Acute NaV1.4 inhibition in adult rats reproduced the aged phenotype, supporting causality

6. 06

   Small-molecule ClC-1 inhibition enhanced muscle contractile function and motor performance in aged, weak rats

Study Design

Translational Study

Sample Size

Not reported

Study Duration

Cross-sectional human assessment plus aged-rodent intervention

Methodology

Cross-species study combining electrophysiological assessment of NMJ transmission in older adults with clinically significant weakness, aged rodent models, immunohistochemistry of the post-synaptic membrane, pharmacological NaV1.4 blockade, and small-molecule ClC-1 inhibition in aged rats.

Limitations

Human data are observational (association between NMJ transmission failure and weakness); every intervention result is rodent. ClC-1 inhibitors have human safety data in myasthenia gravis but no trial in sarcopenia or age-related weakness has been reported. Industry-sponsored.